Quotient Therapeutics

MA - CambridgeBiotechnology5 H-1B visas (FY2023)

Focus: Quotient Therapeutics is a Cambridge-based biotech specializing in genetic library technology for rare diseases. The company is actively conducting early-stage clinical research with a portfolio spanning oncology, neurodegenerative disease, and infectious disease.

Rare Diseases

Profile data last refreshed 13h ago · AI intelligence enriched 1w ago

Open Jobs

106+63 this month

Hot — 94 jobs added in 30d

Net +63 (94 new, 31 removed). Aggressive expansion phase.

Should You Work at Quotient Therapeutics?

AI assessment

Early-stage science-driven opportunity best suited for researchers seeking platform-building work in genetics, with elevated financial uncertainty typical of pre-revenue biotech.

Why Work Here

Strong R&D focus with 28 active positions in research and development, indicating commitment to scientific discovery
Growing data science team (16 roles) suggests investment in computational biology and genetic library platform advancement

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ID-Capsule- Active

Healthy Volunteers

N/A

Clinical Trials (1)

NCT03653897Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence

N/A

Help build intelligence for Quotient Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

100% H1B approval rate (5/5 in 2023) indicates supportive visa sponsorship and talent acquisition strategy

Watch Out For

All 20 clinical programs are Phase 1, meaning no near-term regulatory approvals or revenue inflection; long capital runway required
No disclosed revenue, funding, employee count, or financial metrics create visibility risk around company runway and stability
Zero publications on record and absence of recent news or milestones suggest limited public engagement or clinical validation

Generated by Claude from Quotient Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test a

Diabetes

N/A

Clinical Trials (1)

NCT01829061Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System

N/A

TRx0037

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT01253499Multiple Dose Study of TRx0037

Phase 1

Tolcapone

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03633591A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Phase 1

Zoliflodacin

Gonorrhea

Phase 1

Clinical Trials (1)

NCT03718806Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

Phase 1

amilo-5MER

Inflammatory Disease

Phase 1

Clinical Trials (1)

NCT05857215A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects

Phase 1

Belumosudil 200 mg tablet

Autoimmune Diseases

Phase 1

Clinical Trials (1)

NCT03907540Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

Phase 1

Phenytoin

Not Determined

Phase 1

Belumosudil

Drug-drug Interaction

Phase 1

Clinical Trials (1)

NCT03530995Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Phase 1

Belumosudil Tablet

Bioavailability

Phase 1

Clinical Trials (1)

NCT02557139Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Phase 1

[14C]AZD9833 Oral Solution, 75 mg

ER-positive, HER2-negative Breast Cancer

Phase 1

Clinical Trials (1)

NCT05364255A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Phase 1

anle138b

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT04685265A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

Phase 1

ND0612

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02604914A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Phase 1

Iron Sucrose Injection

Bioequivalance

Phase 1

Clinical Trials (1)

NCT04155814Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

Phase 1

Estetrol

Contraception

Phase 1

Clinical Trials (1)

NCT02720224Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

Phase 1

Ibuprofen

Gastroduodenal Erosions

Phase 1

Clinical Trials (1)

NCT02521207Pilot Study of OXP001(2) and Brufen in Healthy Subjects

Phase 1

MMV371 LAI

Malaria,Falciparum

Phase 1

Clinical Trials (1)

NCT06558643Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Phase 1

HBI-3000

Atrial Fibrillation

Phase 1

Clinical Trials (1)

NCT03397641A Phase 1 Study of HBI-3000

Phase 1

Reference capsule GDC-0134

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT03237741Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Phase 1

AZD0780 tablet

Cardiovascular Diseases

Phase 1

Clinical Trials (1)

NCT05817461An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Phase 1

MMV367

Malaria,Falciparum

Phase 1

Clinical Trials (1)

NCT05507970First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Phase 1

AZD9977 capsule 50 mg

Cardiovascular Disease

Phase 1

Clinical Trials (1)

NCT04686591Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Phase 1

NM-101

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT05790382Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

Phase 1

E4/DRSP

Contraception

Phase 1

Clinical Trials (1)

NCT03512860Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

Phase 1

PUR118

Chronic Obstructive Pulmonary Disease

Phase 1

Clinical Trials (1)

NCT01333904Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118

Phase 1

AZD4604 Inhalation Powder, 1 mg

Asthma

Phase 1

Clinical Trials (1)

NCT06157255An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Phase 1

Tiotropium

Healthy

Phase 1

Zyloprim® 300 mg

Healthy

Phase 1

Clinical Trials (1)

NCT02398448IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Phase 1

MMV055 Dose 1

Malaria, Falciparum

Phase 1

Clinical Trials (1)

NCT07011511Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Phase 1

HTL0009936 modified release

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT02710188Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Phase 1

Capivasertib film-coated tablet, 200 mg

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05419401A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

Phase 1

Part 1: Belumosudil 40 mg/mL Sequence ABFCED

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04735822A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Phase 1

Levodopa/Carbidopa

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT02486432A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)

Phase 1

PUR0200

Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Clinical Trials (1)

NCT01921712A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

Phase 1

PLENVU powder for oral solution

Pharmacokinetic

Phase 1

Clinical Trials (1)

NCT03437265A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Phase 1

800mg OZ439 prototype formulation 1

Malaria

Phase 1

Clinical Trials (1)

NCT02083406Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)

Phase 1

AZD5462 film-coated tablet

Heart Failure

Phase 1

Clinical Trials (1)

NCT06989983A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

Phase 1

14C]AZD4831 Oral Solution

Cardiovascular Disease

Phase 1

Clinical Trials (1)

NCT04407091A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Phase 1

OZ439 + TPGS

Malaria

Phase 1

Clinical Trials (1)

NCT02387580Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets

Phase 1

tiotropium

Healthy

Phase 1

[14C]AZD5718 Oral Suspension

Cardiovascular Disease

Phase 1

Clinical Trials (1)

NCT03948451Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Phase 1

Quizartinib dihydrochloride

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT04796831A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Phase 1

Intravenous Infusion

Asthma

Phase 1

Clinical Trials (1)

NCT04002427Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594

Phase 1

[14C]-Paxalisib Capsule

Healthy

Phase 1

Clinical Trials (1)

NCT05012670Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Phase 1

BC-3781

Healthy

Phase 1

Clinical Trials (1)

NCT03131141A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

Phase 1

Part 1 Group 1 Regime A

Cachexia

Phase 1

Clinical Trials (1)

NCT06028321Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Phase 1

[14C]AZD4954 Oral Solution

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07812077A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954

Phase 1

TRx0037

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT01253122Comparative Bioavailability in Healthy Elderly Volunteers

Phase 1

FMPV-1

Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT05238558Safety and Immune Response to FMPV-1

Phase 1

AZD6234 Formulation 1

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07220954A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Phase 1

Interview Prep Quick Facts

Portfolio: 84 clinical trials

Top TAs: Neurology, Infectious Diseases, Immunology

H-1B (2023): 5 approvals

Open Roles: 106 active jobs

Therapeutic Area Focus

10 pipeline

6 pipeline

4 pipeline

4 pipeline

3 pipeline

Hiring Trend

Actively Hiring

106

Open Roles

+13

Added

-4

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Cardiovascular

2 pipeline

Women's Health

1 pipeline

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Quotient Therapeutics

Should You Work at Quotient Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (106)

Director, Program Lead – Women’s Health and Preeclampsia

Director, Growth Strategy and Operations

Research Associate II, NGS

Associate Director/Director International Accounting and Government Compliance

Sr. Research Systems Analyst

Research Associate I/II, Cloning/IVT (Contract)

Senior Research Associate, Strain Engineering

Research Associate I/II, Bioprocess Development

Research Associate I/II, Formulation & Process Development

Associate Scientist, Analytical Development and Quality Control

UAS Systems Integration Engineer II

Senior Director, Business Development

Pioneering Medicines: Medical Director / Senior Medical Director, Clinical Development Lead

Associate Scientist

Lead Data Engineer

Senior Scientist, Immunology

Director, Clinical Operations

Experimental Systems Intern

Director, Legal Compliance

Lab Operations Manager

Director/Senior Director, Regulatory Counsel

Senior Research Associate, In vivo Pharmacology

Director, Health Data Science

Vice President, AI Research and Real-World Evidence

Senior Research Associate, Molecular Biology and Sequencing

Hiring Trend

Visa Sponsorship